Telix shares surge as much as 14% after its most advanced cancer therapy candidate passes phase III safety and dosimetry hurdles Clarity says it will achieve the targeted 220 patients for its prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results